Abstract: Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
January 7, 2020
Assignee:
UCL BUSINESS LTD
Inventors:
Rajiv Jalan, Rajeshwar Prosad Mookerjee, Krista Rombouts, Fausto Andreola, Francesco De Chiara, Karen Louise Thomsen
Abstract: This invention provides fluid formulations and materials produced therefrom for repairing dental and bone defects, processes for the production of the fluid formulations and materials, and to uses of these formulations and materials. In particular, the invention provides the use cationic polymers such as polylysine in these formulations and materials, and the advantageous properties derived therefrom which include mechanical and antibacterial properties.
Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.
Type:
Grant
Filed:
September 28, 2012
Date of Patent:
November 19, 2019
Assignee:
UCL BUSINESS LTD
Inventors:
Mervyn Singer, John Francis Martin, Alex Peter Dyson